Mycosis fungoides and sezary syndrome: An update (original) (raw)

• Girardi, M, Heald PW, Wilson LD: The pathogenesis of mycosis fungoides. N Engl J Med 2004, 35:1978–1988. A lucid, comprehensive review of the basic science advances in MF/SS.
  Article Google Scholar
• WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768–3785. The new joint classification system is a step in the right direction for clarifying cutaneous lymphomas.
• Pimpinelli N, Olsen EA, Santucci M, et al.: Defining early mycosis fungoides. J Am Acad Dermatol 2005, 53:1053–1063.
  Article PubMed Google Scholar
• Wood GS, Tung RM, Haeffner AC, et al.: Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 1994, 103: 34–41.
  Article PubMed CAS Google Scholar
• Ponti R, Quaglino P, Novelli M, et al.: T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings. Br J Dermatol 2005, 153:565–573.
  Article PubMed CAS Google Scholar
• Alessi E, Coggi A, Venegoni L, et al.: The usefulness of clonality for the detection of cases clinically and/or histopathologically not recognized as cutaneous T-cell lymphoma. Br J Dermatol 2005, 153: 368–371.
  Article PubMed CAS Google Scholar
• Guitart J: Beyond clonal detection: defining the T-cell clone. Arch Dermatol 2005, 141(9):1159–1160. A concise summary of the current role of T-cell receptor clonality in MF/SS diagnosis and prognosis.
  Article PubMed Google Scholar
• Cordel N, Lenormand B, Courville P, et al.: Usefulness of cutaneous T-cell clonality analysis for the diagnosis of cutaneous T-cell lymphoma in patients with erythroderma. Arch Pathol Lab Med 2005, 129:372–376.
  PubMed Google Scholar
• Tracey L, Villuendas R, Dotor AM, et al.: Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003, 102:1042–1050. One of three studies that demonstrate the power of microarray analysis as applied to MF/SS. See [10,11].
  Article PubMed CAS Google Scholar
• Kari L, Loboda A, Nebozhyn M, et al.: Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003, 197:1477–1488. One of three studies that demonstrate the power of microarray analysis as applied to MF/SS. See [9,11].
  Article PubMed CAS Google Scholar
• Nebozhyn M, Loboda A, Kari L, et al.: Quantitative PCR on 5 genes reliably identifies CTCL patients with 5–99% circulating tumor cells with 90% accuracy. Blood 2006, 107:3189–3196. One of three studies that demonstrate the power of microarray analysis as applied to MF/SS. See [9,10].
  Article PubMed CAS Google Scholar
• Vonderheid EC, Bernengo MG: The Sezary syndrome: hematologic criteria. Hematol Oncol Clin North Am 2003, 17:1367–1389, viii. An update of the B classification system for MF/SS that reflects the newer diagnostic techniques.
  Article PubMed Google Scholar
• Beylot-Barry M, Parrens M, Delaunay M, et al.: Is bone marrow biopsy necessary in patients with mycosis fungoides and Sezary syndrome? A histological and molecular study at diagnosis and during follow-up. Br J Dermatol 2005, 152:1378–1379.
  Article PubMed CAS Google Scholar
• Morton LM, Wang SS, Devesa SS, et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006, 107:265–276.
  Article PubMed CAS Google Scholar
• Morales MM, Putcha V, Evans HS, et al.: Survival of mycosis fungoides in patients in the Southeast of England. Dermatology 2005, 211:325–329.
  Article PubMed Google Scholar
• Gupta RK, Ramble J, Tong CY, et al.: Cytomegalovirus seroprevalence is not higher in patients with mycosis fungoides/Sezary syndrome. Blood 2006, 107:1241–1242.
  Article PubMed CAS Google Scholar
• Tothova SM, Bonin S, Trevisan G, Stanta G: Mycosis fungoides: is it a Borrelia burgdorferi-associated disease? Br J Cancer 2006, 94:879–883.
  Article PubMed CAS Google Scholar
• Trento E, Castilletti C, Ferraro C, et al.: Human herpesvirus 8 infection in patients with cutaneous lymphoproliferative diseases. Arch Dermatol 2005, 141:1235–1242.
  Article PubMed Google Scholar
• Morales-Suarez-Varela MM, Olsen J, Johansen P, et al.: Occupational exposures and mycosis fungoides. A European multicentre case-control study (Europe). Cancer Causes Control 2005, 16:1253–1259.
  Article PubMed Google Scholar
• Schmidt A, Robbins J, Zic J: Transformed mycosis fungoides developing after treatment with alefacept. J Am Acad Dermatol 2005, 53:355–356.
  Article PubMed Google Scholar
• Dalle S, Balme B, Berger F, et al.: Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol 2005, 153:207–208.
  Article PubMed CAS Google Scholar
• Abeni D, Frontani M, Sampogna F, et al.: Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 2005, 153:324–330.
  Article PubMed CAS Google Scholar
• Juarez T, Isenhath SN, Polissar NL, et al.: Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol 2005, 141:1107–1113.
  Article PubMed CAS Google Scholar
• Assaf C, Hummel M, Steinhoff M, et al.: Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood 2005, 105:503–510.
  Article PubMed CAS Google Scholar
• Klemke CD, Mansmann U, Poenitz N, et al.: Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol 2005, 153:118–124. This paper offers a revised severity index that, if further validated, could be a valuable tool in future clinical trials and outcome studies.
  Article PubMed Google Scholar
• Kupper TS, Fuhlbrigge RC: Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4:211–222. Excellent review of the role of skin-homing T cells.
  Article PubMed CAS Google Scholar
• Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al.: Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005, 152:258–264.
  Article PubMed CAS Google Scholar
• Kagami S, Sugaya M, Minatani Y, et al.: Elevated serum CTACK/CCL27 levels in CTCL. J Invest Dermatol 2006, 126:1189–1191.
  Article PubMed CAS Google Scholar
• Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al.: Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. Clin Exp Dermatol 2005,30:702–706.
  Article PubMed CAS Google Scholar
• Introcaso CE, Hess SD, Kamoun M, et al.: Association of change in clinical status and change in the percentage of the CD4+CD26-lymphocyte population in patients with Sezary syndrome. J Am Acad Dermatol 2005, 53:428–434.
  Article PubMed Google Scholar
• Narducci MG, Scala E, Bresin A, et al.: Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006, 107:1108–115. This paper elucidates the role of CD26 loss in SS.
  Article PubMed CAS Google Scholar
• Vonderheid EC, Boselli CM, Conroy M, et al.: Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol 2005, 124:651–661.
  Article PubMed CAS Google Scholar
• Talpur R, Jones DM, Alencar AJ, et al.: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006, 126:575–583.
  Article PubMed CAS Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330–336.
  Article PubMed CAS Google Scholar
• Karube K, Ohshima K, Tsuchiya T, et al.: Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004, 126:81–84.
  Article PubMed CAS Google Scholar
• Walsh PT, Benoit BM, Wysocka M, et al.: A role for regulatory T cells in cutaneous T-cell lymphoma: induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection. J Invest Dermatol 2006, 126:690–692. One of two papers that explore the relationship between Treg cells and MF/SS, an emerging area of research. See [37].
  Article PubMed CAS Google Scholar
• Berger CL, Tigelaar R, Cohen J, et al.: Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005, 105:1640–1647. One of two papers that explore the relationship between Treg cells and MF/SS, an emerging area of research. See [36].
  Article PubMed CAS Google Scholar
• Wong HK, Wilson AJ, Gibson HM, et al.: Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides—cutaneous T cell lymphoma. J Invest Dermatol 2006, 126:212–219.
  Article PubMed CAS Google Scholar
• Szabo SJ, Jacobson NG, Dighe AS, et al.: Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995, 2:665–675.
  Article PubMed CAS Google Scholar
• Showe LC, Fox FE, Williams D, et al.: Depressed IL-12-mediated signal transduction in T cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. J Immunol 1999, 163:4073–4079.
  PubMed CAS Google Scholar
• Wysocka M, Zaki MH, French LE, et al.: Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002, 100:3287–3294.
  Article PubMed CAS Google Scholar
• Kim EJ, Hess S, Richardson SK, et al.: Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005, 115:798–812. This review summarizes the immunobiology of MF/SS and the rationale behind combination therapy.
  Article PubMed CAS Google Scholar
• Yamanaka K, Clark R, Dowgiert R, et al.: Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma. Clin Cancer Res 2006, 12:376–382.
  Article PubMed CAS Google Scholar
• Okamura H, Tsutsi H, Komatsu T, et al.: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378:88–91.
  Article PubMed CAS Google Scholar
• Yoshimoto T, Tsutsui H, Tominaga K, et al.: IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 1999, 96:13962–13966.
  Article PubMed CAS Google Scholar
• Dalloul A, Laroche L, Bagot M, et al.: Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest 1992, 90:1054–1060.
  Article PubMed CAS Google Scholar
• Yamanaka K, Clark R, Rich B, et al.: Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006, 107:2440–2445.
  Article PubMed CAS Google Scholar
• Yawalkar N, Ferenczi K, Jones DA, et al.: Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003, 102:4059–4066. One of two papers that demonstrate that MF/SS profoundly decreased normal T-cell repertoire, which may contribute to the immunosuppression observed in these patients. See [49].
  Article PubMed CAS Google Scholar
• Yamanaka K, Yawalkar N, Jones DA, et al.: Decreased Tcell receptor excision circles in cutaneous T-cell lymphoma. Clin Cancer Res 2005, 11:5748–5755. One of two papers that demonstrate that MF/SS profoundly decreased normal T-cell repertoire, which may contribute to the immunosuppression observed in these patients. See [48*].
  Article PubMed CAS Google Scholar
• Rosato RR, Grant S: Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005, 9:809–824.
  Article PubMed CAS Google Scholar
• van Doorn R, Zoutman WH, Dijkman R, et al.: Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005, 23:3886–3896.
  Article PubMed CAS Google Scholar
• Nagasawa T, Zhang Q, Raghunath PN, et al.: Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. Leuk Res 2006, 30:303–312.
  Article PubMed CAS Google Scholar
• Sors A, Jean-Louis F, Pellet C, et al.: Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006, 107:2354–2363.
  Article PubMed CAS Google Scholar
• Querfeld C. Rosen ST, Kuzel TM, et al.: Long-term followup of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005, 141:305–311.
  Article PubMed Google Scholar
• Rupoli S, Goteri G, Pulini S, et al.: Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005, 75:136–145.
  Article PubMed CAS Google Scholar
• Duvic M, Martin AG, Kim Y, et al.: Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001, 137:581–593.
  PubMed CAS Google Scholar
• Budgin JB, Richardson SK, Newton SB, et al.: Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005, 141:315–321.
  Article PubMed CAS Google Scholar
• Gorgun G, Foss F: Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100:1399–1403.
  Article PubMed CAS Google Scholar
• Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106:454–457.
  Article PubMed CAS Google Scholar
• Bouwhuis SA, Davis MD, el-Azhary RA, et al.: Bexarotene treatment of late-stage mycosis fungoides and Sezary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005, 52:991–996.
  Article PubMed Google Scholar
• McGinnis KS, Junkins-Hopkins JM, Crawford G, et al.: Low-dose oral bexarotene in combination with lowdose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004, 50:375–379.
  Article PubMed Google Scholar
• Hino R, Shimauchi T, Tokura Y: Treatment with IFNgamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. J Dermatol Sci 2005, 38:189–195.
  Article PubMed CAS Google Scholar
• Marchi E, Alinari L, Tani M, et al.: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer, 2005. 104(11): 2437–2441.
  Article PubMed CAS Google Scholar
• Molina A, Zain J, Arber DA, et al.: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005, 23:6163–6171. A retrospective review of eight patients treated with bone marrow/ stem cell transplantation, which is increasingly considered for MF/SS patients with refractory disease.
  Article PubMed Google Scholar
• Zhang C, Richon V, Ni X, et al.: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005, 125:1045–1052.
  Article PubMed CAS Google Scholar
• Olsen E, Kim YH, Kuzel T, et al.: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial [abstract]. Proc ASCO 2006 24:7500.
  Google Scholar
• Salskov-Iversen M, Berger CL, Edelson RL: Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading. J Immune Based Ther Vaccines 2005, 3:4.
  Article PubMed CAS Google Scholar
• Lamberg SI, Bunn PA Jr: Proceedings of the Workshop on Cutaneous T-cell Lymphomas (mycosis fungoides and Sezary syndrome). Cancer Treat Rep 1979, 63:561–568.
  PubMed CAS Google Scholar